Product name:Doxycycline Hyclate 100mg/500mg
Company name:
DIN:0081719
Status:Marketed
Status date:2017-02-15
| Active ingredient(s) | Strength |
|---|---|
| 500mg |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
Doxycycline, a broad-spectrum antibiotic, is used for the treatment of various bacterial infections, including skin and soft tissue infections, urinary tract infections (UTIs), respiratory tract infections, and yeast infections. The market for doxycycline is significant and continues to evolve due to its effectiveness, driven by increasing demand for effective antibiotics and the increasing prevalence of antibiotic-resistant strains of bacteria. The doxycycline market size is expected to reach USD 1.2 billion by 2025, growing at a Compound Annual Growth Rate (CAGR) of 2.7% from 2024 to 2533.2 million by an estimated compound annual growth rate (IAT) of 6.4% during the forecast period.
The rising prevalence of antibiotic-resistant bacteria in bacterial patients globally is a major driver of the doxycycline-resistance market. Doxycycline is an effective broad-spectrum antibiotic used for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, respiratory tract infections, and yeast infections. It is effective in the treatment of various bacterial infections by inhibiting the growth and spread of bacteria in the body. Additionally, doxycycline can be used to treat a variety of infections caused by resistant bacteria, including urinary tract infections, skin and soft tissue infections, and other bacterial conditions. These factors contribute to the increasing resistance of bacteria to traditional antibiotics and the development of antibiotic-resistant infections.
Growing awareness and destigmatization of bacterial diseases are significant factors that are boosting the demand for antibiotics like doxycycline. With increased recognition and adoption of doxycycline as a viable treatment option for bacterial infections, the market is expected to grow as more patients seek treatment. The increasing prevalence of antibiotic-resistant bacteria in patients globally is another significant factor that is driving the market growth. The intense global anti-bacterial pressures and the global trend towards increased antibiotic spending have contributed to the growing demand for doxycycline.
The doxycycline-resistance market was valued at USD 1.04 billion in 2023 and is expected to reach USD 1.8 billion by 2034, growing at a CAGR of 2.1% from 2024 to 2533.2 million from 2935 to 2146 from a CAGR of 5.5% from 2935 to 3145.
The market is segmented into two main distribution channels: hospital pharmacies and retail pharmacies. Hospital pharmacies dominate the distribution, with a 46.2% market share, followed by retail pharmacies with a 30.3% market share.
The doxycycline-resistance treatment for bacterial skin infections, such as acne, rosacea, and systemic lupus erythematosis (SLE), is primarily conducted in hospital pharmacies. The segmented market players include Azithromycin, Doxycycline, and Levofloxacin.
The market is expected to experience steady growth due to increased reimbursement policies and rising out-of-pocket costs for patients. The availability of generic versions of antibiotics and the global shift towards lower cost options are key drivers for the market.
The growing prevalence of antibiotic-resistant bacteria in patients worldwide is a significant driver of the doxycycline-recoverable market. With a global population of 4.5 billion and an IOL of 3.1 billion, IOLs represent another significant segment due to their expanding health services and financial resources.
The doxycycline-resistance treatment for bacterial infections is expected to grow significantly due to rising awareness and destigmatization of bacterial diseases and the expansion of antibiotic spending. The growing use of antibiotics and the global trend towards increased spending have contributed to the increasing resistance of bacteria to traditional antibiotics and the development of antibiotic-resistant infections. The IAT of doxycycline is determined by several factors, including the increasing prevalence of antibiotic-resistant bacteria and the global anti-bacterial pressures and the global trend towards increased antibiotic spending.
Give as directed by your veterinarian. Follow the instructions printed on the prescription label. Store doxycycline at room temperature. Be sure to complete the prescription to ensure a full recovery, even if your pet seems to be improving, unless instructed otherwise by your veterinarian. Allow your pet access to plenty of water. Doxycycline can be given with or without food but should not be given with dairy products.
Keep out of the reach of children and pets. Do not use in animals with a known sensitivity to doxycycline. Do not use in pregnant animals. Let your veterinarian know if your pet is on any other medications, as interactions with certain medicines can occur. Do not administer any calcium-containing medications, antacids, laxatives, or multivitamins within 2 hours of the last doxycycline dose. Notify your veterinarian if your animal suffers from kidney or liver disease. Doxycycline may increase skins sensitivity to sunlight. Store at room temperature. Store protected from light and moisture.
Allergic reactions and serious side effects are rare, but in the case of an allergic reaction or a serious side effect you should stop doxycycline treatment and seek veterinary attention. Some common signs of allergic reactions and serious side effects are hives, breathing difficulty, facial swelling, loss of appetite, or dark colored urine.
Should be stored at room temperature, away from moisture and heat.
Doxycycline should not be used in animals allergic to it or other tetracycline antibiotics. Use with caution in animals with impaired liver or kidney function. Do not use in pregnant, nursing, or growing animals since this medication may cause slowing of bone growth and discoloration of teeth. Give antacids, vitamin and mineral combinations, iron, or Pepto-Bismol at least 1 hour before or 4 hours after giving doxycycline. Use caution when given with digoxin or warfarin. Doxycycline is not affected by food.
Read the Consent Limited Association Consent Act before using this medicine. You may not use this medicine for a period of 6 weeks or more. You should not give this medicine to a person less than 18 years old if you have coughing or breathing problems or if the brand name Doxycycline has a low risk of causing a serious allergic reaction. If you give this medicine to a person less than 18 years old, talk to your veterinarian.ShareThis document is commissioned by the Pharmaceutical Council of Singapore. It is not intended to promote quality, safety or anonymous drug information. Copyright 2024pharmcocrinol. All rights reserved. Singapore Pharmaceutical CouncilView more see linkDrug InformationSinus infections (sinusitis and sinusitis) are a common and serious bacterial infection. There are different types of antibiotics that can treat sinus infections and many different types of antibiotics can be used to treat infections in the sinus.
Antibiotics are medicines that belong to a group of medicines called antibiotics. Antibiotics are normally used to treat bacterial infections to treat anaerobic infections. When a person has a sinus infection, there are different types of antibiotics that can be used to treat it. These include:
Antibiotics that treat infections in the sinuses, which may include
Types of antibiotics that can be used to treat infections in the sinuses
Types of antibiotics that can be used to treat sinus infections such as
Types of antibiotics that can be used to treat sinus infections such as cephalosporins,
Types of antibiotics that can be used to treat sinus infections such as cephalosporins
View moreSee Drug InformationProduct InformationYes, Doxycycline capsules can be effective in treating acne. They are commonly prescribed by healthcare professionals for moderate to severe acne cases. Doxycycline is an antibiotic that works by reducing inflammation and controlling the growth of bacteria associated with acne.
Doxycycline helps to improve acne symptoms by:
Reducing inflammation: Doxycycline has anti-inflammatory properties that can help reduce the redness, swelling, and tenderness associated with acne.
Controlling bacterial growth: Acne is often caused by the overgrowth of bacteria on the skin, particularly a type of bacteria called Propionibacterium acnes. Doxycycline works by inhibiting bacterial protein synthesis, thereby controlling the growth and spread of these bacteria.
Regulating oil production: Doxycycline can also help regulate sebum (oil) production in the skin, which is a contributing factor in the development of acne.
You should combine systemic antibiotics such as doxycycline or capsules (both contraindicated in pregnancy and children under 12 years of age) with an appropriate topical agent such as or or. You should ideally continue treatment for 3 months.
Add your below directed dose information.You should always combine systemic antibiotics such as doxycycline or capsules (either alone or in combination) with an appropriate topical agent such as or. You should ideally combine systemic antibiotics with an agent that inhibits bacterial protein synthesis or with an agent that stimulates sebum production.
You should avoid using other medications that increase inflammation, such as aspirin and ibuprofen. These medications may also be used to treat conditions that are listed as antibiotics in the medication guide.You should always avoid using topical antibiotics such as or to treat acne if you have underlying health conditions or are taking other medications.
If you are pregnant, you are advised to avoid systemic antibiotics as it can cause harm to the developing fetus and may cause birth defects in the foetus.
If you are breastfeeding, you are advised to avoid systemic antibiotics as it can cause harm to the developing baby.
If you are taking oral contraceptives or other types of hormonal contraceptives, you are advised to avoid systemic antibiotics as they may cause harm to the developing fetus and may cause birth defects in the foetus.
If you are pregnant, you are advised to avoid systemic antibiotics as they may cause harm to the developing baby.
Stade de France Pharmacy